

47-2020-10898 | Novel Activating Antibodies for Viral Treatment  
[Levi-Schaffer Francesca](#), HUJI, School of Medicine - IMRIC, School of Pharmacy- Institute for Drug Research

Various pathogens (bacteria and viruses as well) bind to specific cell adhesion molecule in order to inhibit the immune response and/or to infect the host cells. However, upon binding and induction/activation, the cell adhesion molecule suppresses virus production by an SHP2-dependent process which involves also suppression of mTOR-mediated protein biosynthesis.

We propose our anti- cell adhesion molecule activating mAb as a broad antiviral therapy (including Covid-19) that will:

- Bind the cell membrane cell adhesion molecule in various lung (i.e. endothelial, epithelial dendritic and other) cells and stimulate anti-viral activity in these lung cells expressing the cell adhesion molecule .
- Bind and mask cell surface and virus associated cell adhesion molecule and render the possibility of Covid-19 cell adhesion molecule homotypic interaction with host cell and the following infection less feasible.

#### Patent Status

Contact for more information:



Keren-Or Amar  
VP, Business Development, Healthcare

**Yissum Research Development Company of the Hebrew University of Jerusalem**

Hi-Tech Park, Edmond J. Safra Campus, Givat-Ram, Jerusalem  
P.O. Box 39135, Jerusalem 91390 Israel  
Telephone: 972-2-658-6688, Fax: 972-2-658-6689